SCHEMBL313799

SCHEMBL313799

Brc1cnc2c(c1)-n1c(nnc1-c1ccccc1)CCN2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.46
CYP11B2 P19099 2/20 0.46
CYP17A1 P05093 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP19A1 P11511 1/20 0.46
CYP11B1 P15538 1/20 0.46
BRD4 O60885 1/20 0.40
AKT1 P31749 8/20 0.36
HPGD P15428 2/20 0.35
ALDH1A1 P00352 1/20 0.34
GRM5 P41594 1/20 0.34
GABRA1 P14867 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
DYRK1B Q9Y463 1/20 0.33
PLK4 O00444 1/20 0.33
AURKA O14965 1/20 0.33
JAK2 O60674 1/20 0.33
ROCK2 O75116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL314129 0.91 TSHR (0.41) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL314776 0.85 TSHR (0.40) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL316222 0.74 BRD4 (0.69) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL10098573 0.71 BRD4 (0.50) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL12841365 0.70 TSHR (0.62) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL314704 0.64 BRD4 (0.57) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL12841355 0.64 TSHR (0.50) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL313900 0.64 HPGD (0.48) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL15463795 0.63 CYP11B2 (1.00) TSHRCYP11B2CYP17A1CYP3A4CYP19A1
SCHEMBL314814 0.63 BRD4 (0.46) TSHRCYP11B2CYP17A1CYP3A4CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP claimed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US claimed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
US-8093240-B2 Triazole derivatives MERCK PATENT GMBH (DE) 2012-01-10 US disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
EP-2322527-A1 Triazole derivatives Merck Patent GmbH (DE) 2011-05-18 EP disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
US-20080306042-A1 Triazole Derivatives MERCK PATENT GMBH (DE) 2008-12-11 US disclosed
WO-2007079820-A1 TRIAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306042-A1 Triazole Derivatives TGFBR1, TGFBR2, SMAD3 TSHR 244/4885CYP11B2 2270/4885CYP17A1 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.